BIBW 2992 Plus Simvastatin 9 q: A8 S; k- a5 p S
Detailed Description:
( l( x# T& z& v+ dOne of the main reasons of resistance to EGFR tyrosine kinase inhibitors (TKIs) is that there are alternative mechanisms for persistent activating EGFR downstream signaling, including both RAS/Erk and PI3K/Akt kinase pathways. Therefore, simultaneous inhibition of both pathways would be necessary to reduce tumor cell survival more effectively. One of the candidate combinations is concurrent use of EGFR-TKIs and statins, which are irreversible inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and have been used to treat hypercholesterolemia through blocking the mevalonate biosynthesis pathway. Beside the cholesterol lowering effect, statins have been shown to induce apoptosis in several tumor types. It affects the synthesis of other products of the mevalonate pathway such as isoprenoids, which are used as substrates for prenylation. Attachment of isoprenoids to RAS proteins facilitates their anchoring to the cell membrane where they carried out their roles. By interrupting the biosynthesis of mevalonate, statins inhibit activation of RAS and downstream signaling cascades, including the RAF/MEK/ERK and PI3K/AKT, which play critical roles in regulation of cell survival and proliferation. Therefore, it seems to be a promising therapeutic approach overcoming tumor resistance to EGFR-TKIs, which is associated with RAS activation.
5 i- c ^1 D( |# \2 {/ m; C, T
" E& s+ [, y# H! p& G1 J. zAccording to the recent clinical result of phase II trial, a randomized phase II study of gefitinib with or without simvastatin in previously treated patients with advanced NSCLC conducted by Han et al.37 gefitinib plus simvastatin combination produced higher response rates than gefitinib alone in patients with non-adenocarcinoma (5/13 [39%] v 1/13 [8%], P=0.06). This finding suggests that simvastatin may enhance sensitivity to gefitinib in non-adenocarcinoma that is relatively resistant to gefitinib. Moreover, by Mantha et al.35 demonstrated that the combination of gefitinib and lovastatin showed significant synergic cytotoxic effects in vitro in a total of 16 squamous cell carcinomas, NSCLC, and colon carcinoma cell lines. Of special interest, these cell lines did not possess the activating mutations of EGFR, which confer increased sensitivity to gefitinib. Nevertheless, combining lovastatin with gefitinib induced more significant inhibition of AKT activation than either agent alone. Additionally, lovastatin significantly enhanced the sensitivity to gefitinib treatment regardless PTEN loss in glioblastoma cell lines. These results suggest that statins can augment EGFR inhibition.
- A* d2 s1 q# F) G( e( L; T0 T S, o' F: r2 T! H
|
肺癌患者靶向药耐药后，选择免疫治疗
作者：闵
靶向治疗与免疫治疗是当下肿瘤治疗的两个重要方向，然而自免疫治疗上市以来
父亲的治疗传来了好消息
父亲今年68岁，从今年三月低确认肺癌晚期到现在，一直没有好消息。胸水基因检测：EGFR
晚期肺癌13年靶向轮换之路，我总结9
讲述者：不怕辣椒不怕癌整理者：雪漓
上篇文章中分享了我家13年抗癌经历以及心态成长
关于聘请注册ID“yddhu”微信名Dan作
论坛注册用户“yddhu”，微信名“Dan”（病友常亲切的称呼为蛋总），在论坛的官方微信
从胃炎到胃癌，身体的求救信号你读懂
作者：Tony
每年的11月是我国的“胃癌防治宣传月”。根据 2022 年全球癌症报告显示，
显身卡
